Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH

NCT01212796 | Unknown DMC

• 2 other identifiers: GET-ALO-2010-01get-alo-2010-01
• Study Type: observational
• Target: 350
• Locations: 0 countries
• Sites: N/A

Brief Summary

The allogeneic hematopoietic stem cell marrow is the only curative treatment for many hematologic malignancies. However, many patients relapse in these situations to be therapeutic possibilities scarce and mixed. Chemotherapy in these situations does not show good results and new drugs have not yet demonstrated the effectiveness desired. Another therapeutic approach after relapse post allogeneic transplant is to resubmit the allogeneic transplant patient to patient. In this clinical situation is little known. All previous studies are retrospective, the data provided are of little statistical value and heterogeneous patient samples. The GETH (Grupo Espanol de trasplantes hematopoyeticos y terapia celular) has included in its database a figure around 350 seconds allogeneic transplants. Comparing this with the studies published so far, this would be the largest retrospective series published size compared to second allogeneic transplants.

Conditions

Allogeneic Stem Cell Transplantation

Keywords

allogeneic stem cell transplantation

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who underwent 2 or more allogeneic transplants in Spanish hospitals between the beginning of monitoring and the end of 2009, end of follow-up.

You may qualify if:

• patients who underwent 2 or more allogeneic transplants and the beginning of monitoring and the end of 2009, end of follow-up.

Sponsors & Collaborators

• Grupo Espanol de trasplantes hematopoyeticos y terapia celular: lead

Study Officials

• Duarte R Palomino, MD

  Grupo Espanol de trasplantes hematopoyeticos y terapia celular

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Duarte R Palomino, MD

CONTACT

34 666458025; rduarte@iconcologia.net

Orti G Pascual, Data Manager

CONTACT

gorti@iconcologia.net

Study Design

• Study Type: observational
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 30, 2010
• First Posted: October 1, 2010
• Study Start: September 1, 2010
• Primary Completion: March 1, 2011
• Study Completion: June 1, 2011
• Last Updated: October 1, 2010

Record last verified: 2010-09